The Nubeqa anti-cancer drug developed in Turku estimated to have 3 billion euros in global sales potential
Orion’s collaboration partner Bayer has upgraded estimate on Nubeqa’s (darolutamide) peak sales potential. According to Bayer’s new estimate, in Turku developed Nubeqa’s annual global peak sales could exceed EUR 3 billion. Earlier Bayer has anticipated that Nubeqa’s annual global peak sales could exceed EUR 1 billion.
Bayer holds global commercial rights to darolutamide and Orion is entitled to receive annually tiered royalties on global darolutamide sales. The total annual royalty rate is approximately 20% including product sales to Bayer. Initially the total annual royalty rate will be slightly lower, and as sales increase, the total annual royalty rate will increase. Orion manufactures the product for global markets and co-promotes the product in Europe with Bayer.
In addition to royalties, Orion is entitled to receive progressive one-off milestone payments from Bayer that may total EUR 280 million, depending on the future sales development of Nubeqa.
The drug required for refining Nubeqa is manufactured at Orion’s plant in Hanko, and the Nubeqa pills themselves are made at Orion’s Espoo plant. The finalized medicines are packaged in Salo.